Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Bipolar Disord. 2022 Apr 15;24(7):709–719. doi: 10.1111/bdi.13208

Table 2.

An informational table completed by each site

Mean (SD) Range Distribution** Shapiro-Wilk (p) Descriptor
LEVEL ONE MEASURES --- --- --- ---
Age In years e.g., first episode
Sex %Female
Race %White
Education level In years Primary/secondary
LEVEL TWO MEASURES --- --- --- ---
BD subtype %BDI/BDII/NOS
Psychosis Hx %yes/no Lifetime presence
Current depressive sx HDRS/MDRS score mild/mod/severe
Current manic sx YMRS/other score mild/mod/severe
Age at onset dep In years
Age at onset mania In years
# Prior manias
#Prior depressions
# total episodes Full mania/depression
#Hospitalizations
#Suicide attempts
Comorbid substance dx %yes/no Lifetime presence
Comorbid anxiety dx %yes/no Lifetime presence
LEVEL THREE MEASURES --- --- --- ---
Global cognition Calculated g using PCA
Premorbid IQ e.g., proxy WRAT/NART
Medications
Lithium % Yes
Anticonvulsants % Yes
Antipsychotics % Yes
Antidepressants % Yes
Benzodiazepines % Yes
Total number of psychotropic meds Mean (SD)
--- --- --- --- ---
OUTCOME MEASURES
Global functioning Provide name of scale
Global functioning impaired Provide name of scale
Social functioning Provide name of scale
Occupational fx Provide name of scale
Independent living Provide name of scale
Employed Yes/no
**

Shapiro-Wilk test for normality should be reported for each measure